PIK3CA and nasopharyngeal carcinoma: Thus, we performed the long-term treatment over 7 days to further evaluate the potencies of NVP-BEZ235 on NPC cells, and found that there were different inhibitory effects between PIK3CA wild-type CNE1 cells and PIK3CA mutant cells.